STERIS (NYSE:STE) Director Cynthia Feldmann Sells 3,098 Shares

STERIS plc (NYSE:STE) Director Cynthia Feldmann sold 3,098 shares of STERIS stock in a transaction on Thursday, March 5th. The shares were sold at an average price of $237.21, for a total transaction of $734,876.58. Following the completion of the sale, the director directly owned 705 shares of the company’s stock, valued at approximately $167,233.05. The trade was a 81.46% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

STERIS Trading Down 3.4%

STERIS stock opened at $230.49 on Friday. STERIS plc has a one year low of $204.90 and a one year high of $269.44. The company’s fifty day moving average price is $254.37 and its two-hundred day moving average price is $251.51. The company has a debt-to-equity ratio of 0.26, a current ratio of 2.48 and a quick ratio of 1.75. The company has a market capitalization of $22.60 billion, a price-to-earnings ratio of 32.15 and a beta of 1.05.

STERIS (NYSE:STE) last announced its quarterly earnings results on Wednesday, February 4th. The medical equipment provider reported $2.53 earnings per share for the quarter, hitting analysts’ consensus estimates of $2.53. STERIS had a return on equity of 14.34% and a net margin of 12.15%.The firm’s revenue was up 9.2% compared to the same quarter last year. During the same period in the previous year, the company earned $2.32 earnings per share. STERIS has set its FY 2026 guidance at 10.150-10.300 EPS. On average, analysts forecast that STERIS plc will post 9.08 earnings per share for the current fiscal year.

STERIS Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, March 19th. Stockholders of record on Tuesday, February 17th will be given a $0.63 dividend. The ex-dividend date of this dividend is Tuesday, February 17th. This represents a $2.52 dividend on an annualized basis and a dividend yield of 1.1%. STERIS’s dividend payout ratio (DPR) is currently 35.15%.

Institutional Trading of STERIS

A number of hedge funds have recently modified their holdings of the company. Mediolanum International Funds Ltd lifted its holdings in shares of STERIS by 9.0% during the 2nd quarter. Mediolanum International Funds Ltd now owns 62,327 shares of the medical equipment provider’s stock worth $14,883,000 after acquiring an additional 5,156 shares during the period. Entropy Technologies LP increased its stake in STERIS by 282.2% in the second quarter. Entropy Technologies LP now owns 9,099 shares of the medical equipment provider’s stock valued at $2,186,000 after acquiring an additional 6,718 shares during the period. Vanguard Group Inc. raised its position in STERIS by 1.7% in the second quarter. Vanguard Group Inc. now owns 12,163,128 shares of the medical equipment provider’s stock worth $2,921,827,000 after purchasing an additional 205,276 shares in the last quarter. Asset Management One Co. Ltd. raised its holdings in shares of STERIS by 5.4% in the 3rd quarter. Asset Management One Co. Ltd. now owns 98,487 shares of the medical equipment provider’s stock worth $24,366,000 after buying an additional 5,072 shares in the last quarter. Finally, Cerity Partners LLC grew its position in STERIS by 28.8% in the third quarter. Cerity Partners LLC now owns 96,853 shares of the medical equipment provider’s stock valued at $23,966,000 after acquiring an additional 21,656 shares during the period. Institutional investors own 94.69% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on the stock. Wall Street Zen upgraded shares of STERIS from a “buy” rating to a “strong-buy” rating in a research note on Saturday. Weiss Ratings reaffirmed a “buy (b)” rating on shares of STERIS in a research report on Friday, January 9th. Six equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $275.20.

STERIS Company Profile

STERIS Corporation (NYSE: STE) is a global provider of infection prevention, contamination control and procedural products and services for the healthcare, life sciences, pharmaceutical and medical device industries. The company develops, manufactures and supports a broad portfolio of equipment and consumables designed to reduce risk of infection, maintain sterile environments and support critical clinical and manufacturing procedures.

Its offerings include sterilization and decontamination systems, instrument washers and washers-disinfectors, endoscope reprocessing solutions, surgical equipment and procedural disposables, and contamination-control products for cleanrooms and laboratories.